Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
September 2016
-
Media ReleaseNew Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 yearsACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya® (fingolimod) had significantly lower disability progression compared to those…
-
Media ReleaseNovartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraineDetailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine…
-
Three lessons I’ve learned as an industry postdoc
An immunologist shares tips from a team-based environment
-
Media ReleaseNovartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy CongressEmerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries Retrospective…
-
Reaping cancer clues from the blood
NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics
-
Media ReleaseNew Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisionsNijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
-
A cellular drama at the heart of a researcher’s family
Jennifer Allport-Anderson hunts for cardiac cures.
-
Media ReleaseAlcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experienceHeads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue[1] Offers enhanced 3D visualization with high-definition resolution, image…
-
Media ReleaseNovartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groupsUltibro® Breezhaler® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered…
-
Giving a small community a big voice
Read a patient’s perspective on living with a rare, life-threatening blood cancer called myelofibrosis and why it’s important to rally the community.
August 2016
-
Media ReleaseAirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatmentNew study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving…
-
Media ReleaseFDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseasesErelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
Pagination
- ‹ Previous page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- …
- 152
- › Next page